New hope for rare blood cancers: drug cocktail targets tough lymphomas
NCT ID NCT07339527
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called zeprumetostat, combined with either golidocitinib or chidamide, in 60 adults with relapsed or refractory mature T-cell and NK-cell lymphomas. The goal is to find safe doses and see if the combination shrinks tumors. It is an early-phase trial, so the main focus is safety and initial effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zeprumetostat (EZH2 inhibitor) combined with golidocitinib or chidamide
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat T-cell and NK-cell lymphomas.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. Combination therapies also carry higher risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE T-CELL AND NK-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.